Menu
Back to User profile » Professor Nicola A Hanania
Papers published by Professor Nicola A Hanania:
Novel Anti-Inflammatory Approaches to COPD
Cazzola M, Hanania NA, Page CP, Matera MG
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1333-1352
Published Date: 29 June 2023
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
Maspero JF, Bachert C, Martinez FJ, Hanania NA, Ortiz B, Patel N, Mannent LP, Praestgaard A, Pandit-Abid N, Siddiqui S, Hardin M
Journal of Asthma and Allergy 2023, 16:333-342
Published Date: 31 March 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:407-418
Published Date: 24 March 2023
Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
Hanania NA, Maspero JF, Halpin DM, Jackson DJ, Panettieri RA, Castro M, Domingo C, Daizadeh N, Gall R, Jacob-Nara JA, Ortiz B, Djandji M, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2022, 15:851-854
Published Date: 28 June 2022
Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home
Ari A, Blain K, Soubra S, Hanania NA
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2687-2695
Published Date: 28 September 2021
Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD
Strollo HC, Nouraie SM, Hoth KF, Riley CM, Karoleski C, Zhang Y, Hanania NA, Bowler RP, Bon J, Sciurba FC
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2515-2522
Published Date: 3 September 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials
Hanania NA, Caveney S, Soule T, Tombs L, Lettis S, Crim C, Mannino DM, Patel H, Boucot IH
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1925-1938
Published Date: 24 June 2021
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
Hanania NA, Yohannes AM, Ozol-Godfrey A, Tocco M, Goodin T, Sharma S, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:865-875
Published Date: 31 March 2021
Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy
Quirce S, Heffler E, Nenasheva N, Demoly P, Menzies-Gow A, Moreira-Jorge A, Nissen F, Hanania NA
Journal of Asthma and Allergy 2020, 13:743-752
Published Date: 31 December 2020
Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions
Hanania NA, O'Donnell DE
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1127-1138
Published Date: 24 May 2019
Targeting IL-5 in COPD
Narendra DK, Hanania NA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1045-1051
Published Date: 16 May 2019
Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma
Brooks EA, Massanari M, Hanania NA, Weiner DJ
ClinicoEconomics and Outcomes Research 2019, 11:301-307
Published Date: 17 April 2019
Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD
Hanania NA, Sethi S, Koltun A, Ward JK, Spanton J, Ng D
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:117-127
Published Date: 27 December 2018
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2805-2819
Published Date: 7 September 2018
Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial
Donohue JF, Bollu VK, Stull DE, Nelson LM, Williams VSL, Stensland MD, Hanania NA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:499-508
Published Date: 5 February 2018
A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges
Cazzola M, Hanania NA, MacNee W, Rüdell K, Hackford C, Tamimi N
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:725-738
Published Date: 7 April 2015
Optimizing care of your patients with COPD
Garvey C, Hanania NA, Altman P
Nursing: Research and Reviews 2014, 4:7-18
Published Date: 21 February 2014
Ten years of tiotropium: clinical impact and patient perspectives
Yohannes AM, Connolly MJ, Hanania NA
International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:117-125
Published Date: 15 March 2013
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease
Decramer ML, Hanania NA, Lötvall JO, Yawn BP
International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:53-64
Published Date: 25 January 2013